Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.oregonlive.com/entertainment/2020/02/oregons-bearded-builders-team-on-competing-in-tvs-lego-masters-the
Are you over 18 and want to see adult content?
A complete backup of www.ladepeche.fr/2020/02/01/amber-heard-reconnait-avoir-frappe-johnny-depp-je-suis-tellement-en-colere-que-
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of thesource.com/2020/02/28/lil-baby-my-turn-2/
Are you over 18 and want to see adult content?
A complete backup of www.vrplayground.de/facebook-sagt-f8-ab/
Are you over 18 and want to see adult content?
A complete backup of sports.yahoo.com/sydney-fc-0-1-western-112604439.html
Are you over 18 and want to see adult content?
A complete backup of www.khaosod.co.th/entertainment/news_3657443
Are you over 18 and want to see adult content?
Text
MRNA VACCINES
According to Pardi et al., the first advantage is safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis.Additionally, mRNA is degraded by normal cellular processes, and the in vivo half-life can be regulated through the use of various modifications and delivery methods.The inherent immunogenicity of the mRNA can alsoIRDYE® 800
IRDyes This product is licensed for sales only for research use. Notwithstanding the foregoing, this product may not be used in diagnostic, therapeutic or human in vivo applications. Commerical Use is prohibited. Commercial Use shall include: 1. resales, lease, license or other transfer of the material or any material derived orproduced from it.
CLEANCAP® REAGENT AG (3' OME) CleanCap ® Reagent AG (3' OMe) is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency1. CleanCap AG (3' OMe) includes the 5' N7-Methyl-3'-O-Methylguanosine commonly found in mRNA capped using ARCA, whereas CleanCap AG (N-7113) has a naturally MRNA CAPPING ANALOGS, CAPPING ENZYMES & MORE Cap Analogs. 5’ cap structure of messenger RNA (mRNA) prevents degradation of the mRNA in the cytoplasm and promotes ribosome recruitment and protein translation. Cap analogs can be used to initiate transcription which eliminates the need for an additional enzymatic capping step. Sort by: CLEANCAP® CRE MRNA (5MOU) NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites. This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method,which results in
5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. THE MODIFIED NUCLEIC ACID EXPERTS TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap ® mRNA capping technology. CLEANCAP® REAGENT AG CleanCap ® Reagent AG is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency. PLEASE NOTE: TriLink recommends using CleanCap AG whenever possible. CleanCap AG requires an AG initiator. CLEANCAP® EGFP MRNA Description. The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm. This mRNA is capped using CleanCap, TriLink'sMRNA VACCINES
According to Pardi et al., the first advantage is safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis.Additionally, mRNA is degraded by normal cellular processes, and the in vivo half-life can be regulated through the use of various modifications and delivery methods.The inherent immunogenicity of the mRNA can alsoIRDYE® 800
IRDyes This product is licensed for sales only for research use. Notwithstanding the foregoing, this product may not be used in diagnostic, therapeutic or human in vivo applications. Commerical Use is prohibited. Commercial Use shall include: 1. resales, lease, license or other transfer of the material or any material derived orproduced from it.
CLEANCAP® REAGENT AG (3' OME) CleanCap ® Reagent AG (3' OMe) is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency1. CleanCap AG (3' OMe) includes the 5' N7-Methyl-3'-O-Methylguanosine commonly found in mRNA capped using ARCA, whereas CleanCap AG (N-7113) has a naturally MRNA CAPPING ANALOGS, CAPPING ENZYMES & MORE Cap Analogs. 5’ cap structure of messenger RNA (mRNA) prevents degradation of the mRNA in the cytoplasm and promotes ribosome recruitment and protein translation. Cap analogs can be used to initiate transcription which eliminates the need for an additional enzymatic capping step. Sort by: CLEANCAP® CRE MRNA (5MOU) NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites. This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method,which results in
5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. CLEANCAP | TRILINK BIOTECHNOLOGIES CleanCap ® technology is a proprietary, co-transcriptional 5’ capping solution that generates a natural Cap 1 structure. Proper mRNA capping is critical to the production of the most biologically active and least immunogenic mRNA. TriLink scientists developed CleanCap, the next generation of capping technology, as a solution to the low THERMOSTABLE RNA VACCINE DELIVERY PROMISES ENHANCED Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response. RNA-based vaccines offer several advantages over traditional vaccines. These include faster production, simpler scale-up, and more rapid adaptability to new targets. Such factors have proven critical in tackling the ongoing COVID-19 pandemic, allowing vaccines targetingSARS
MRNA CAPPING ANALOGS, CAPPING ENZYMES & MORE Cap Analogs. 5’ cap structure of messenger RNA (mRNA) prevents degradation of the mRNA in the cytoplasm and promotes ribosome recruitment and protein translation. Cap analogs can be used to initiate transcription which eliminates the need for an additional enzymatic capping step. Sort by: CLEANCAP® FLUC MRNA FLuc is commonly used in mammalian cell culture to measure both gene expression and cell viability. It emits bioluminescence in the presence of the substrate, luciferin. This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with highcapping efficiency.
5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
N 1 -METHYLPSEUDOURIDINE-5'-TRIPHOSPHATE N1-Methyl-Pseudouridine-5'-Triphosphate is a modified NTP for incorporation into messenger RNAs (mRNA) using T7 RNA Polymerase. Incorporation of N1-methylpseudouridine can reduce the immunogenicity of the resulting mRNA. 5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. PERSPECTIVES ON PLASMIDS FOR IVT MRNA PRODUCTION—PART 1 Plasmids Were Discovered in 1952 as Agents of “Genetic Exchange” Between Bacteria In the Last 50 Years, There Have Been Over 200,000 Plasmid Publications, Averaging 15 Per Day During 1990-2020 Plasmids Provide the Starting Point for IVT mRNA Production TriLink Continuereading →
SAFETY DATA SHEET
SAFETY DATA SHEET Version 4 2020‐04‐17 T Page 1 of 5 1. IDENTIFICATION 1.1 Product Identifiers Product Name(s): CleanCap AUCleanCap Reagent AU
2-AMINO-2'-DEOXYADENOSINE-5'-TRIPHOSPHATE Description. Substitution of 2-Amino-2'-deoxyadenosine (also known as 2,6-Diaminopurine-2'-deoxyribose) for adenine in DNA can result in increased stabilization of the DNA duplex. Diaminopurine base pairs with thymine forming three intramolecular hydrogen bonds versus twofor adenine.
THE MODIFIED NUCLEIC ACID EXPERTS TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap ® mRNA capping technology. CLEANCAP® REAGENT AG CleanCap ® Reagent AG is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency. PLEASE NOTE: TriLink recommends using CleanCap AG whenever possible. CleanCap AG requires an AG initiator. CLEANCAP® EGFP MRNA Description. The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm. This mRNA is capped using CleanCap, TriLink'sMRNA VACCINES
According to Pardi et al., the first advantage is safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis.Additionally, mRNA is degraded by normal cellular processes, and the in vivo half-life can be regulated through the use of various modifications and delivery methods.The inherent immunogenicity of the mRNA can alsoIRDYE® 800
IRDyes This product is licensed for sales only for research use. Notwithstanding the foregoing, this product may not be used in diagnostic, therapeutic or human in vivo applications. Commerical Use is prohibited. Commercial Use shall include: 1. resales, lease, license or other transfer of the material or any material derived orproduced from it.
CLEANCAP® REAGENT AG (3' OME) CleanCap ® Reagent AG (3' OMe) is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency1. CleanCap AG (3' OMe) includes the 5' N7-Methyl-3'-O-Methylguanosine commonly found in mRNA capped using ARCA, whereas CleanCap AG (N-7113) has a naturally CLEANCAP® CRE MRNA (5MOU) NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites. This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method,which results in
5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. 2-AMINO-2'-DEOXYADENOSINE-5'-TRIPHOSPHATE Description. Substitution of 2-Amino-2'-deoxyadenosine (also known as 2,6-Diaminopurine-2'-deoxyribose) for adenine in DNA can result in increased stabilization of the DNA duplex. Diaminopurine base pairs with thymine forming three intramolecular hydrogen bonds versus twofor adenine.
THE MODIFIED NUCLEIC ACID EXPERTS TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap ® mRNA capping technology. CLEANCAP® REAGENT AG CleanCap ® Reagent AG is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency. PLEASE NOTE: TriLink recommends using CleanCap AG whenever possible. CleanCap AG requires an AG initiator. CLEANCAP® EGFP MRNA Description. The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm. This mRNA is capped using CleanCap, TriLink'sMRNA VACCINES
According to Pardi et al., the first advantage is safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis.Additionally, mRNA is degraded by normal cellular processes, and the in vivo half-life can be regulated through the use of various modifications and delivery methods.The inherent immunogenicity of the mRNA can alsoIRDYE® 800
IRDyes This product is licensed for sales only for research use. Notwithstanding the foregoing, this product may not be used in diagnostic, therapeutic or human in vivo applications. Commerical Use is prohibited. Commercial Use shall include: 1. resales, lease, license or other transfer of the material or any material derived orproduced from it.
CLEANCAP® REAGENT AG (3' OME) CleanCap ® Reagent AG (3' OMe) is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency1. CleanCap AG (3' OMe) includes the 5' N7-Methyl-3'-O-Methylguanosine commonly found in mRNA capped using ARCA, whereas CleanCap AG (N-7113) has a naturally CLEANCAP® CRE MRNA (5MOU) NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites. This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method,which results in
5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. 2-AMINO-2'-DEOXYADENOSINE-5'-TRIPHOSPHATE Description. Substitution of 2-Amino-2'-deoxyadenosine (also known as 2,6-Diaminopurine-2'-deoxyribose) for adenine in DNA can result in increased stabilization of the DNA duplex. Diaminopurine base pairs with thymine forming three intramolecular hydrogen bonds versus twofor adenine.
CLEANCAP | TRILINK BIOTECHNOLOGIES CleanCap ® technology is a proprietary, co-transcriptional 5’ capping solution that generates a natural Cap 1 structure. Proper mRNA capping is critical to the production of the most biologically active and least immunogenic mRNA. TriLink scientists developed CleanCap, the next generation of capping technology, as a solution to the low THERMOSTABLE RNA VACCINE DELIVERY PROMISES ENHANCED Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response. RNA-based vaccines offer several advantages over traditional vaccines. These include faster production, simpler scale-up, and more rapid adaptability to new targets. Such factors have proven critical in tackling the ongoing COVID-19 pandemic, allowing vaccines targetingSARS
MRNA CAPPING ANALOGS, CAPPING ENZYMES & MORE Cap Analogs. 5’ cap structure of messenger RNA (mRNA) prevents degradation of the mRNA in the cytoplasm and promotes ribosome recruitment and protein translation. Cap analogs can be used to initiate transcription which eliminates the need for an additional enzymatic capping step. Sort by: 5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
PSEUDOURIDINE-5'-TRIPHOSPHATE Pseudouridine (5-ribosyluracil) was the first modified ribonucleoside discovered. It is the most abundant natural modified RNA base, and has been deemed the "fifth nucleoside" in RNA. It can be found in structural RNAs, such as transfer, ribosomal and small nuclear RNA. Pseudouridine has been found to enhance base stacking and translation. 5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. N 1 -METHYLPSEUDOURIDINE-5'-TRIPHOSPHATE N1-Methyl-Pseudouridine-5'-Triphosphate is a modified NTP for incorporation into messenger RNAs (mRNA) using T7 RNA Polymerase. Incorporation of N1-methylpseudouridine can reduce the immunogenicity of the resulting mRNA. PERSPECTIVES ON PLASMIDS FOR IVT MRNA PRODUCTION—PART 1 Plasmids Were Discovered in 1952 as Agents of “Genetic Exchange” Between Bacteria In the Last 50 Years, There Have Been Over 200,000 Plasmid Publications, Averaging 15 Per Day During 1990-2020 Plasmids Provide the Starting Point for IVT mRNA Production TriLink Continuereading →
MRNA DELIVERY FOR THERAPEUTIC ANTI-HER2 ANTIBODY IN VIVO The remainder of this blog will focus on a recent report by Rybakova et al. that, for the first time, demonstrates the delivery of an IVT-mRNA in vivo to express a fully functional anticancer antibody designed to mimic the monoclonal antibody trastuzumab, sold under the brand name Herceptin.In this instance, unmodified IVT-mRNAs of heavy and light chains were co-delivered in a protective lipid SPECIFICITY ENHANCEMENT OF PCR AND OTHER DNA Following the invention of PCR in 1983 by Kary Mullis (1993 Nobel Prize in Chemistry), dNTPαS analogs were shown to be useful in PCR-based applications such as DNA sequencing by either chemical degradation (Gish and Eckstein), exonuclease digestion (Labeit et al.), or pyrosequencing (Gharizadeh et al.).. In the early literature for polymerase-mediated incorporation of dNTPαS THE MODIFIED NUCLEIC ACID EXPERTS TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap ® mRNA capping technology. CLEANCAP® REAGENT AG CleanCap ® Reagent AG is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency. PLEASE NOTE: TriLink recommends using CleanCap AG whenever possible. CleanCap AG requires an AG initiator. CLEANCAP® EGFP MRNA Description. The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm. This mRNA is capped using CleanCap, TriLink'sMRNA VACCINES
According to Pardi et al., the first advantage is safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis.Additionally, mRNA is degraded by normal cellular processes, and the in vivo half-life can be regulated through the use of various modifications and delivery methods.The inherent immunogenicity of the mRNA can alsoIRDYE® 800
IRDyes This product is licensed for sales only for research use. Notwithstanding the foregoing, this product may not be used in diagnostic, therapeutic or human in vivo applications. Commerical Use is prohibited. Commercial Use shall include: 1. resales, lease, license or other transfer of the material or any material derived orproduced from it.
CLEANCAP® REAGENT AG (3' OME) CleanCap ® Reagent AG (3' OMe) is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency1. CleanCap AG (3' OMe) includes the 5' N7-Methyl-3'-O-Methylguanosine commonly found in mRNA capped using ARCA, whereas CleanCap AG (N-7113) has a naturally CLEANCAP® CRE MRNA (5MOU) NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites. This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method,which results in
5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. 2-AMINO-2'-DEOXYADENOSINE-5'-TRIPHOSPHATE Description. Substitution of 2-Amino-2'-deoxyadenosine (also known as 2,6-Diaminopurine-2'-deoxyribose) for adenine in DNA can result in increased stabilization of the DNA duplex. Diaminopurine base pairs with thymine forming three intramolecular hydrogen bonds versus twofor adenine.
THE MODIFIED NUCLEIC ACID EXPERTS TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap ® mRNA capping technology. CLEANCAP® REAGENT AG CleanCap ® Reagent AG is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency. PLEASE NOTE: TriLink recommends using CleanCap AG whenever possible. CleanCap AG requires an AG initiator. CLEANCAP® EGFP MRNA Description. The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm. This mRNA is capped using CleanCap, TriLink'sMRNA VACCINES
According to Pardi et al., the first advantage is safety: as mRNA is a non-infectious, non-integrating platform, there is no potential risk of infection or insertional mutagenesis.Additionally, mRNA is degraded by normal cellular processes, and the in vivo half-life can be regulated through the use of various modifications and delivery methods.The inherent immunogenicity of the mRNA can alsoIRDYE® 800
IRDyes This product is licensed for sales only for research use. Notwithstanding the foregoing, this product may not be used in diagnostic, therapeutic or human in vivo applications. Commerical Use is prohibited. Commercial Use shall include: 1. resales, lease, license or other transfer of the material or any material derived orproduced from it.
CLEANCAP® REAGENT AG (3' OME) CleanCap ® Reagent AG (3' OMe) is TriLink’s proprietary co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency1. CleanCap AG (3' OMe) includes the 5' N7-Methyl-3'-O-Methylguanosine commonly found in mRNA capped using ARCA, whereas CleanCap AG (N-7113) has a naturally CLEANCAP® CRE MRNA (5MOU) NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites. This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method,which results in
5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. 2-AMINO-2'-DEOXYADENOSINE-5'-TRIPHOSPHATE Description. Substitution of 2-Amino-2'-deoxyadenosine (also known as 2,6-Diaminopurine-2'-deoxyribose) for adenine in DNA can result in increased stabilization of the DNA duplex. Diaminopurine base pairs with thymine forming three intramolecular hydrogen bonds versus twofor adenine.
CLEANCAP | TRILINK BIOTECHNOLOGIES CleanCap ® technology is a proprietary, co-transcriptional 5’ capping solution that generates a natural Cap 1 structure. Proper mRNA capping is critical to the production of the most biologically active and least immunogenic mRNA. TriLink scientists developed CleanCap, the next generation of capping technology, as a solution to the low THERMOSTABLE RNA VACCINE DELIVERY PROMISES ENHANCED Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic Response. RNA-based vaccines offer several advantages over traditional vaccines. These include faster production, simpler scale-up, and more rapid adaptability to new targets. Such factors have proven critical in tackling the ongoing COVID-19 pandemic, allowing vaccines targetingSARS
ARCA | TRILINK BIOTECHNOLOGIES Description. Trusted TriLink quality, exceptional price. A key step in cellular mRNA processing is the addition of a 5’ cap structure, which is a 5'-5' triphosphate linkage between the 5' end of the RNA and a guanosine nucleotide. The cap is methylated enzymatically at theN-7
5-METHYLCYTIDINE-5'-TRIPHOSPHATE Methylation of the 5 position of cytidine is a common, post-transcriptional modification in a number of RNA species, such as mRNA, miRNA and tRNA. 5-Methylcytidine-5'-Triphosphate (5-Methyl-CTP) is a modified nucleoside triphosphate employed to impart desirable characteristics such as increased nuclease stability, increasedtranslation or
MRNA CAPPING ANALOGS, CAPPING ENZYMES & MORE Cap Analogs. 5’ cap structure of messenger RNA (mRNA) prevents degradation of the mRNA in the cytoplasm and promotes ribosome recruitment and protein translation. Cap analogs can be used to initiate transcription which eliminates the need for an additional enzymatic capping step. Sort by: 5-FORMYLCYTIDINE-5'-TRIPHOSPHATE 11,000 Lmol -1 cm -1 at 283 nm. Molecular Formula. C 10 H 16 N 3 O 15 P 3 (free acid) Molecular Weight. 511.10 g/mole (free acid) Salt Form. Li+. Concentration. 100 mM. N 1 -METHYLPSEUDOURIDINE-5'-TRIPHOSPHATE N1-Methyl-Pseudouridine-5'-Triphosphate is a modified NTP for incorporation into messenger RNAs (mRNA) using T7 RNA Polymerase. Incorporation of N1-methylpseudouridine can reduce the immunogenicity of the resulting mRNA. PERSPECTIVES ON PLASMIDS FOR IVT MRNA PRODUCTION—PART 1 Plasmids Were Discovered in 1952 as Agents of “Genetic Exchange” Between Bacteria In the Last 50 Years, There Have Been Over 200,000 Plasmid Publications, Averaging 15 Per Day During 1990-2020 Plasmids Provide the Starting Point for IVT mRNA Production TriLink Continuereading →
MRNA DELIVERY FOR THERAPEUTIC ANTI-HER2 ANTIBODY IN VIVO The remainder of this blog will focus on a recent report by Rybakova et al. that, for the first time, demonstrates the delivery of an IVT-mRNA in vivo to express a fully functional anticancer antibody designed to mimic the monoclonal antibody trastuzumab, sold under the brand name Herceptin.In this instance, unmodified IVT-mRNAs of heavy and light chains were co-delivered in a protective lipid SPECIFICITY ENHANCEMENT OF PCR AND OTHER DNA Following the invention of PCR in 1983 by Kary Mullis (1993 Nobel Prize in Chemistry), dNTPαS analogs were shown to be useful in PCR-based applications such as DNA sequencing by either chemical degradation (Gish and Eckstein), exonuclease digestion (Labeit et al.), or pyrosequencing (Gharizadeh et al.).. In the early literature for polymerase-mediated incorporation of dNTPαS JAVASCRIPT SEEMS TO BE DISABLED IN YOUR BROWSER. For the best experience on our site, be sure to turn on Javascript in your browser. TriLink Biotechnologies is part of Maravai LifeSciences. Learn More* Sign In
*
Canada
Use the up and down arrows to select a result. Press enter to go to the selected search result. Touch device users can use touch and swipegestures.
Search
Toggle Nav
* Products & Services CDMO Service Solutions CleanCap® mRNA Capping Plasmid DNA ProductionGMP Services
Custom mRNA SynthesismRNAbuilder™
mRNAbuilder™
Oligo Manufacturing
OLIGObuilder®
DNA Oligos
RNA Oligos
Mid and Large Scale OligosOligo Modification
OLIGObuilder®
DNA Oligos
RNA Oligos
Mid and Large Scale OligosOligo Modification
Contract Manufacturing (OEM) Custom Chemistry SolutionsBioconjugation
Phosphorylation
Phosphoramidites & SupportsBioconjugation
Phosphorylation
Phosphoramidites & Supports CleanCap® mRNA Capping Plasmid DNA ProductionGMP Services
Custom mRNA SynthesismRNAbuilder™
mRNAbuilder™
Oligo Manufacturing
OLIGObuilder®
DNA Oligos
RNA Oligos
Mid and Large Scale OligosOligo Modification
OLIGObuilder®
DNA Oligos
RNA Oligos
Mid and Large Scale OligosOligo Modification
Contract Manufacturing (OEM) Custom Chemistry SolutionsBioconjugation
Phosphorylation
Phosphoramidites & SupportsBioconjugation
Phosphorylation
Phosphoramidites & SupportsDiscovery Products
Catalog mRNA
Reporter Gene mRNA
Genome Editing mRNA
Gene Replacement mRNAAntigen mRNA
Reporter Gene mRNA
Genome Editing mRNA
Gene Replacement mRNAAntigen mRNA
Nucleoside Triphosphates & NucleotidesBase Modified NTPs
Sugar Modified NTPs
Phosphate Modified NTPsCap Analogs
Non-Nucleotides
Bisphosphate NucleosidesDinucleotides
Labeled Mono- and Triphosphates Unmodified dNTPs & NTPsShow more >
Base Modified NTPs
Sugar Modified NTPs
Phosphate Modified NTPsCap Analogs
Non-Nucleotides
Bisphosphate NucleosidesDinucleotides
Labeled Mono- and Triphosphates Unmodified dNTPs & NTPsShow more >
Hot Start PCR & RT-PCR Reagents CleanAmp® Master MixesCleanAmp® dNTPs
CleanAmp® Master MixesCleanAmp® dNTPs
Sequencing Reagents
CleanTag® Small RNA SequencingImmunoprecipitation
Mitochondrial DNA Sequencing Primers CleanTag® Small RNA SequencingImmunoprecipitation
Mitochondrial DNA Sequencing PrimersCatalog mRNA
Reporter Gene mRNA
Genome Editing mRNA
Gene Replacement mRNAAntigen mRNA
Reporter Gene mRNA
Genome Editing mRNA
Gene Replacement mRNAAntigen mRNA
Nucleoside Triphosphates & NucleotidesBase Modified NTPs
Sugar Modified NTPs
Phosphate Modified NTPsCap Analogs
Non-Nucleotides
Bisphosphate NucleosidesDinucleotides
Labeled Mono- and Triphosphates Unmodified dNTPs & NTPsShow more >
Base Modified NTPs
Sugar Modified NTPs
Phosphate Modified NTPsCap Analogs
Non-Nucleotides
Bisphosphate NucleosidesDinucleotides
Labeled Mono- and Triphosphates Unmodified dNTPs & NTPsShow more >
Hot Start PCR & RT-PCR Reagents CleanAmp® Master MixesCleanAmp® dNTPs
CleanAmp® Master MixesCleanAmp® dNTPs
Sequencing Reagents
CleanTag® Small RNA SequencingImmunoprecipitation
Mitochondrial DNA Sequencing Primers CleanTag® Small RNA SequencingImmunoprecipitation
Mitochondrial DNA Sequencing Primers CDMO Service Solutions CleanCap® mRNA Capping Plasmid DNA ProductionGMP Services
Custom mRNA SynthesismRNAbuilder™
mRNAbuilder™
Oligo Manufacturing
OLIGObuilder®
DNA Oligos
RNA Oligos
Mid and Large Scale OligosOligo Modification
OLIGObuilder®
DNA Oligos
RNA Oligos
Mid and Large Scale OligosOligo Modification
Contract Manufacturing (OEM) Custom Chemistry SolutionsBioconjugation
Phosphorylation
Phosphoramidites & SupportsBioconjugation
Phosphorylation
Phosphoramidites & Supports CleanCap® mRNA Capping Plasmid DNA ProductionGMP Services
Custom mRNA SynthesismRNAbuilder™
mRNAbuilder™
Oligo Manufacturing
OLIGObuilder®
DNA Oligos
RNA Oligos
Mid and Large Scale OligosOligo Modification
OLIGObuilder®
DNA Oligos
RNA Oligos
Mid and Large Scale OligosOligo Modification
Contract Manufacturing (OEM) Custom Chemistry SolutionsBioconjugation
Phosphorylation
Phosphoramidites & SupportsBioconjugation
Phosphorylation
Phosphoramidites & SupportsDiscovery Products
Catalog mRNA
Reporter Gene mRNA
Genome Editing mRNA
Gene Replacement mRNAAntigen mRNA
Reporter Gene mRNA
Genome Editing mRNA
Gene Replacement mRNAAntigen mRNA
Nucleoside Triphosphates & NucleotidesBase Modified NTPs
Sugar Modified NTPs
Phosphate Modified NTPsCap Analogs
Non-Nucleotides
Bisphosphate NucleosidesDinucleotides
Labeled Mono- and Triphosphates Unmodified dNTPs & NTPsShow more >
Base Modified NTPs
Sugar Modified NTPs
Phosphate Modified NTPsCap Analogs
Non-Nucleotides
Bisphosphate NucleosidesDinucleotides
Labeled Mono- and Triphosphates Unmodified dNTPs & NTPsShow more >
Hot Start PCR & RT-PCR Reagents CleanAmp® Master MixesCleanAmp® dNTPs
CleanAmp® Master MixesCleanAmp® dNTPs
Sequencing Reagents
CleanTag® Small RNA SequencingImmunoprecipitation
Mitochondrial DNA Sequencing Primers CleanTag® Small RNA SequencingImmunoprecipitation
Mitochondrial DNA Sequencing PrimersCatalog mRNA
Reporter Gene mRNA
Genome Editing mRNA
Gene Replacement mRNAAntigen mRNA
Reporter Gene mRNA
Genome Editing mRNA
Gene Replacement mRNAAntigen mRNA
Nucleoside Triphosphates & NucleotidesBase Modified NTPs
Sugar Modified NTPs
Phosphate Modified NTPsCap Analogs
Non-Nucleotides
Bisphosphate NucleosidesDinucleotides
Labeled Mono- and Triphosphates Unmodified dNTPs & NTPsShow more >
Base Modified NTPs
Sugar Modified NTPs
Phosphate Modified NTPsCap Analogs
Non-Nucleotides
Bisphosphate NucleosidesDinucleotides
Labeled Mono- and Triphosphates Unmodified dNTPs & NTPsShow more >
Hot Start PCR & RT-PCR Reagents CleanAmp® Master MixesCleanAmp® dNTPs
CleanAmp® Master MixesCleanAmp® dNTPs
Sequencing Reagents
CleanTag® Small RNA SequencingImmunoprecipitation
Mitochondrial DNA Sequencing Primers CleanTag® Small RNA SequencingImmunoprecipitation
Mitochondrial DNA Sequencing Primers* GMP
Manufacturing ServicesGMP Manufacturing
Manufacturing for DiagnosticsGMP Manufacturing
Manufacturing for Diagnostics Manufacturing ServicesGMP Manufacturing
Manufacturing for DiagnosticsGMP Manufacturing
Manufacturing for Diagnostics* Applications
Therapeutics and Drug DiscoveryVaccine Development
Cell Therapy
IVD and Molecular DxPCR & RT-PCR
Mutagenesis
Reporter Genes
CRISPR
Gene Editing
_In vitro_ Transcription Next-Generation Sequencing (NGS) Photocrosslinking Studies Epigenetics & DNA Damage Therapeutics and Drug DiscoveryCRISPR
Vaccine Development
Gene Editing
Cell Therapy
_In vitro_ Transcription IVD and Molecular Dx Next-Generation Sequencing (NGS)PCR & RT-PCR
Photocrosslinking StudiesMutagenesis
Epigenetics & DNA DamageReporter Genes
* Education Center
Resources
TriLink PublicationsPosters
Citations
Videos
Research Spotlight
Brochures
Certificate of Analysis TriLink PublicationsPosters
Citations
Videos
Research Spotlight
Brochures
Certificate of Analysis Oligo Modification InfoFAQs
Technical Articles
Zone in with Zon BlogmRNA Basics
Resources
TriLink PublicationsPosters
Citations
Videos
Research Spotlight
Brochures
Certificate of Analysis TriLink PublicationsPosters
Citations
Videos
Research Spotlight
Brochures
Certificate of Analysis Oligo Modification InfoFAQs
Technical Articles
Zone in with Zon BlogmRNA Basics
* Contact us
* About us
CUSTOM AND STOCKED SOLUTIONS FOR COVID-19 PROGRAMS. CleanCap® mRNA for rapid vaccine development and top-tier oligos to power diagnostic kits Contact Us for Immediate Response CLEANCAP® SETS A NEW STANDARD FOR SUPERIOR MRNA TRANSLATION. Find out how CleanCap® technology reduces cost while increasingefficiency.
Learn More
GETTING TO THE CLINIC ISHARD ENOUGH
So we've made mRNA manufacturing much easier Introducing GMP plasmid manufacturing services for your mRNA-basedtherapeutic
Learn More
COMPLETE MRNA SOLUTIONS TriLink has expanded our facility to offer custom plasmid DNA production services, as well as enhanced scale-up manufacturing of CleanCap® mRNA capping solutions and small molecules.Learn more
CUSTOM AND STOCKED SOLUTIONS FOR COVID-19 PROGRAMS. CleanCap® mRNA for rapid vaccine development and top-tier oligos to power diagnostic kits Contact Us for Immediate Response CLEANCAP® SETS A NEW STANDARD FOR SUPERIOR MRNA TRANSLATION. Find out how CleanCap® technology reduces cost while increasingefficiency.
Learn More
GETTING TO THE CLINIC ISHARD ENOUGH
So we've made mRNA manufacturing much easier Introducing GMP plasmid manufacturing services for your mRNA-basedtherapeutic
Learn More
COMPLETE MRNA SOLUTIONS TriLink has expanded our facility to offer custom plasmid DNA production services, as well as enhanced scale-up manufacturing of CleanCap® mRNA capping solutions and small molecules.Learn more
prev
next
TriLink BioTechnologies is actively responding to the COVID-19 pandemic. Learn More > ABOUT TRILINK BIOTECHNOLOGIES TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO helping life science leaders and innovators overcome challenges in the synthesis and scale-up of nucleic acids, NTPs and mRNA capping analogs with scale-up expertise and unique mRNA production capabilities, including its proprietary CleanCap® mRNA capping technology. TriLink continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity at its new global headquarters to support therapeutic, vaccine and diagnostic customers. CDMO SERVICE SOLUTIONSGMP
mRNA Synthesis
Custom Chemistry
Oligo Synthesis
DISCOVERY PRODUCTS
Hot Start PCR & RT-PCR ReagentsNucleotides
Next Generation Sequencing ReagentsStocked mRNAs
CLEANCAP® - OPTIMIZED CO-TRANSCRIPTIONAL CAPPING FOR VACCINE AND THERAPEUTIC APPLICATIONS. Achieve optimal capping results.Learn More
UPCOMING EVENTS
MRNA BASICS: GETTING STARTED WITH GMP MRNA MANUFACTURINGWebinar
June 15, 2021 - June 15, 2021See Details
TIDES DIGITAL WEEK: MRNA TECHNOLOGIES, THERAPEUTICS AND VACCINESVirtual Talk
June 29, 2021 - June 29, 2021See Details
See All Events
------------------------- A CLEAR PATH TO THE CLINIC. Robust service offerings, with the phases and support you need to see your project to completion.Learn More
LATEST RESEARCH
A Novel Base-Editing Strategy Promises to Treat Sickle Cell DiseaseLearn More
Benefits of Enzyme-Mediated Extracellular Vesicle EngineeringLearn More
Thermostable RNA Vaccine Delivery Promises Enhanced Pandemic ResponseLearn More
KNOWLEDGE IS POWER. INSIGHT TO FUEL YOUR PROJECTS. The TriLink Education Center is an innovation resource hub. Read the latest in technical articles, research updates, publications, andmore.
Learn More
Stay informed of the latest product releases, technical content, and upcoming events. Sign UpSERVICES
* Custom mRNA
* Custom Oligos
* CleanCap
* Custom Chemistry Services* OEM
PRODUCTS
* Stocked mRNAs
* Nucleoside Triphosphates & Nucleotides * Hot Start PCR & RT-PCR Reagents * Sequencing ReagentsGMP
* GMP Manufacturing
* Diagnostic ManufacturingAPPLICATIONS
* Drug Discovery/Therapeutics* CRISPR
* Cell Therapy
* Vaccine Development* Gene Editing
* In Vitro Transcription * IVD & Molecular Dx * Next-Generation Sequencing (NGS)* PCR & RT-PCR
* Photocrosslinking Studies* Mutagenesis
* Epigenetics/DNA Damage* Reporter Genes
ORDERING
* Placing an Order
* Terms & Conditions * Payment/Shipping Terms* Returns
* Legal Notices
* International DistributorsEDUCATION CENTER
* TriLink Publications* Posters
* Citations
* Videos
* Technical Articles * Research Spotlight* FAQ
* Oligo Modification Information* Blog
ABOUT US
* About
* Careers
* Press Room
* Events
* Quality Policy
* EHS Policy
* Environmental Policy* Contact Us
* Community
ISO 9001:2015 Certificate of ApprovalCONNECT
* __
* __
* __
* __
VISIT MARAVAI LIFE SCIENCES AND ITS OTHER BRANDS Copyright 2021 TriLink BioTechnologies. All Rights Reserved. Terms | Privacy Policy |Legal Notices ""
Loading...
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0